Molecular pathogenesis of ovarian clear cell carcinoma

被引：31
|
作者：
Gounaris, Ioannis [1 ]
Brenton, James D. [1 ]
机构：
[1] Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 09期
关键词：
ARID1A; endometriosis; genetically engineered mouse models; glycogen; HNF1B; ovarian clear; PIK3CA cell cancer; IDENTIFIES FREQUENT MUTATION; ARID1A PROTEIN EXPRESSION; SWI/SNF-RELATED COMPLEXES; HYPOXIA-INDUCIBLE FACTOR; REMODELING GENE ARID1A; ENDOMETRIAL CANCER; THERAPEUTIC TARGET; GLYCOGEN-SYNTHESIS; TUMOR-SUPPRESSOR; PTEN EXPRESSION;
D O I：
10.2217/fon.15.45
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ovarian clear cell carcinoma is a distinct subtype of epithelial ovarian cancer, characterized by an association with endometriosis, glycogen accumulation and resistance to chemotherapy. Key driver events, including ARID1A mutations and HNF1B overexpression, have been recently identified and their functional characterization is ongoing. Additionally, the role of glycogen in promoting the malignant phenotype is coming under scrutiny. Appreciation of the notion that ovarian clear cell carcinoma is essentially an ectopic uterine cancer will hopefully lead to improved animal models of the disease, in turn paving the way for effective treatments.
引用
收藏
页码：1389 / 1405
页数：17
相关论文
共 50 条
  • [21] Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma
    Eltabbakh, GH
    Mount, SL
    Beatty, B
    Simmons-Arnold, L
    Cooper, K
    JOURNAL OF SURGICAL ONCOLOGY, 2006, 93 (05) : 379 - 386
  • [22] Ovarian clear cell carcinoma in Cowden Syndrome
    Yauy, K.
    Imbert-Bouteille, M.
    Bubien, V.
    Lindet-Bourgeois, C.
    Rathat, G.
    Perrochia, H.
    MacGrogan, G.
    Bessis, D.
    Tinat, J.
    Baert-Desurmont, S.
    Blanluet, M.
    Vande Perre, P.
    Baudry, K.
    Pujol, P.
    Corsini, C.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1558 - 1559
  • [23] Leiomyosarcoma with Synchronous Clear Cell Ovarian Carcinoma
    Rettenmaier, Mark
    Epstein, Howard D.
    Abaid, Lisa N.
    Bechtol, Karen A.
    Goldstein, Bram H.
    ONKOLOGIE, 2010, 33 (12): : 695 - 697
  • [24] Tumor heterogeneity in ovarian clear cell carcinoma
    Huang, Ruby Yun-Ju
    CANCER RESEARCH, 2024, 84 (05)
  • [25] Translational genomics of ovarian clear cell carcinoma
    Khalique, Saira
    Lord, Christopher J.
    Banerjee, Susana
    Natrajan, Rachael
    SEMINARS IN CANCER BIOLOGY, 2020, 61 : 121 - 131
  • [26] The unique metabolome of clear cell ovarian carcinoma
    Ji, Jennifer X.
    Hoang, Lien N.
    Cochrane, Dawn R.
    Lum, Amy
    Senz, Janine
    Farnell, David
    Tessier-Cloutier, Basile
    Huntsman, David G.
    Geltink, Ramon I. Klein
    JOURNAL OF PATHOLOGY, 2024, 264 (02): : 160 - 173
  • [27] Ovarian clear cell carcinoma - An examination of relapses
    Nguyen, P.
    Wong, F.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 225 - 226
  • [28] Napsin A as a marker of clear cell ovarian carcinoma
    Skirnisdottir, Ingiridur
    Bjersand, Kathrine
    Akerud, Helena
    Seidal, Tomas
    BMC CANCER, 2013, 13
  • [29] Chromosomal abnormalities in ovarian clear cell carcinoma
    Dent, J
    Perren, T
    Wilkinson, N
    Richmond, I
    Markham, A
    Bell, S
    BRITISH JOURNAL OF CANCER, 2001, 85 : 73 - 73
  • [30] Ovarian Clear Cell Carcinoma in Cowden Syndrome
    Yauy, Kevin
    Imbert-Bouteille, Marion
    Bubien, Virginie
    Lindet-Bourgeois, Clothilde
    Rathat, Gauthier
    Perrochia, Helene
    MacGrogan, Gaetan
    Longy, Michel
    Bessis, Didier
    Tinat, Julie
    Baert-Desurmont, Stephanie
    Blanluet, Maud
    Vande Perre, Pierre
    Baudry, Karen
    Pujol, Pascal
    Corsini, Carole
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01): : 7 - 11
12345